NDA 022023 · Merck and CO INC
Emend
Fosaprepitant Dimeglumine · Intravenous
NovelLast checked: Nov 21, 2026Latest source record: May 2, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Jan 25, 2008
Approved uses
5
Original approval plus efficacy supplements
Registered trials
21
7 Phase 3, 0 recruiting
FAERS reports
19,186
17,114 serious, 3,248 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 20, 2026.
EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use ( 1 ) EMEND has not been studied for treatment of established nausea and vomiting. Limitations of Use EMEND has not been studied for the treatment of established nausea and vomiting.
Mechanism: Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 2, 2022 Supplement 21 · Efficacy LetterLabel
- Apr 3, 2018 Supplement 17 · Efficacy · priority review LabelLetterPediatric Medical Review
- Feb 1, 2016 Supplement 6 · Efficacy LabelLetter
- Nov 12, 2010 Supplement 4 · Efficacy ReviewLetterLabel
- Jan 25, 2008 Original approval · Type 1 - New Molecular Entity NovelPediatric Written RequestPediatric Amendment 1Pediatric Amendment 2
2 products under this application
- EMEND · FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
- EMEND · FOSAPREPITANT DIMEGLUMINE EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fosaprepitant Dimeglumine" as an intervention, any sponsor and status, largest first.
- Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.Status unknown
Xijing HospitalAcademic, hospital or other
NCT05755659 · 3,000 participants (planned) · Start Jul 15, 2022 · Primary completion Oct 20, 2024
Drug: Fosaprepitant Dimeglumine for Injection · For: Neoplasms
Sites: Xi'an, China
- Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00619359 · 2,322 participants · Start Feb 2008 · Primary completion Jun 2009
Drug: Comparator: fosaprepitant dimeglumine; Comparator: Aprepitant and 3 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01594749 · 1,015 participants · Start Sep 24, 2012 · Primary completion Nov 3, 2014
Drug: Fosaprepitant dimeglumine; Fosaprepitant Placebo and 5 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00337727 · 848 participants · Start Jan 1, 2007 · Primary completion Oct 28, 2008
Drug: aprepitant; Comparator: ondansetron and 4 more · For: Chemotherapy-Induced Nausea and Vomiting
- Clinical Study of HR20013 for Injection in Patients With Malignant Solid TumorsPivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT05509634 · 754 participants · Start Sep 21, 2022 · Primary completion Jun 19, 2023
Drug: HR20013 for injection;dexamethasone; fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone · For: Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Sites: Guangzhou, China
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic ChemotherapyPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT03578081 · 690 participants · Start Nov 20, 2018 · Primary completion Nov 8, 2021
Drug: Palonosetron Hydrochloride; Ondansetron Hydrochloride and 3 more · For: Malignant Neoplasm
Sites: Birmingham, Alabama; Fairbanks, Alaska; Kingman, Arizona · 566 sites in all
- To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.Pivotal-lookingCompleted
Qilu Pharmaceutical Co., Ltd.Industry
NCT07081256 · 665 participants · Start Jan 3, 2025 · Primary completion Aug 25, 2025
Drug: QLM2010 for injection;dexamethasone; fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone · For: Chemotherapy-Induced Nausea and Vomiting
Sites: Hangzhou, China
- Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly CisplatinPivotal-lookingCompleted
Odense University HospitalAcademic, hospital or other
NCT01074697 · 246 participants · Start Apr 2010 · Primary completion Apr 2015
Drug: Fosaprepitant dimeglumine; Placebo · For: Nausea; Vomiting; Genital Neoplasms, Female
Sites: Adelaide SA, Australia; Aarhus, Denmark; Copenhagen, Denmark · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea2,321
- fatigue2,054
- pyrexia1,734
- dyspnoea1,696
- diarrhoea1,674
- vomiting1,605
- off label use1,489
- alopecia1,412
- rash1,330
- hypersensitivity1,248
- decreased appetite1,172
- pruritus1,138
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 127 |
| 2005 | 134 |
| 2006 | 145 |
| 2007 | 181 |
| 2008 | 177 |
| 2009 | 216 |
| 2010 | 351 |
| 2011 | 479 |
| 2012 | 764 |
| 2013 | 691 |
| 2014 | 818 |
| 2015 | 1,057 |
| 2016 | 1,325 |
| 2017 | 894 |
| 2018 | 1,376 |
| 2019 | 1,393 |
| 2020 | 1,186 |
| 2021 | 1,275 |
| 2022 | 1,170 |
| 2023 | 1,246 |
| 2024 | 1,848 |
| 2025 | 1,439 |
| 2026 | 894 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Emend (Aprepitant)
2024 spending
$123K
Beneficiaries
15
49 claims
Per beneficiary
$8,193
$253.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $54,636 |
| 2021 | $28,372 |
| 2022 | $76,475 |
| 2023 | $61,588 |
| 2024 | $122,902 |
Part D: Emend (Fosaprepitant Dimeglumine)
2024 spending
$7K
Beneficiaries
n/a
21 claims
Per beneficiary
n/a
$193.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $48,894 |
| 2021 | $5,848 |
| 2022 | $2,438 |
| 2023 | $0 |
| 2024 | $7,355 |
Part B: Emend* (Fosaprepitant Dimeglumine*) · HCPCS J1453
2024 spending
$2.2M
Beneficiaries
21,354
104,356 claims
Per beneficiary
$103
2024 ASP limit $0.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $51,275,458 |
| 2021 | $13,921,518 |
| 2022 | $2,823,785 |
| 2023 | $2,419,136 |
| 2024 | $2,206,841 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics and Safety of Fosaprepitant Dimeglumine in Healthy Chinese Volunteers: Bioequivalence Study.
Lu K, Lin S, Wang Y, et al. · Clin Pharmacol Drug Dev 2021 · Comparative Study, Randomized Controlled Trial
- Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome.
Cristofori F, Thapar N, Saliakellis E, et al. · Aliment Pharmacol Ther 2014 · Clinical Trial
- Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A, Birgegård G · Oncology 2015 · Comparative Study, Randomized Controlled Trial
- NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin.
Yeo W, Lau TK, Kwok CC, et al. · BMJ Support Palliat Care 2022 · Clinical Trial
- Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS, Tawa M, Chau NG, et al. · BMC Cancer 2017 · Case Reports, Meta-Analysis
- Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties.
Ridhurkar DN, Ansari KA, Kumar D, et al. · Drug Dev Ind Pharm 2013 · Clinical Trial, Controlled Clinical Trial
Sponsor: Merck and CO INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.